Recent Findings from Thomas Jefferson University Provides New Insights into Cutaneous T-Cell Lymphoma (Increased Risk of Cutaneous T-cell Lymphoma Development After Dupilumab Use for Atopic Dermatitis).

A recent study conducted by researchers at Thomas Jefferson University in Philadelphia has found that the use of the drug dupilumab for treating atopic dermatitis (AD) is associated with an increased risk of developing cutaneous T-cell lymphoma (CTCL). The study, which analyzed data from over 1 million patients, revealed that patients treated with dupilumab had a higher relative risk of developing CTCL compared to those who were not treated with the drug. The risk was highest within the first year of therapy and in adult patients. The findings suggest that caution should be exercised when using dupilumab in certain patient groups. [Extracted from the article]